Yok
Yok
Yok
Background Comparing treatment modalities is difficult in Behcet's syndrome, even if tumour necrosis factor-alpha (TNF-α) inhibitors are a treatment option for all involvements resistant to conventional therapy. This study evaluated how different departments dealt with treatment, particularly with TNF-α inhibitors.
Material and Methods The study comprised 111 patients from our Behcet's syndrome cohort who were treated with TNF-α inhibitors between 2010 and 2019. Data on patients were retrieved retrospectively from the rheumatology, ophthalmology, and dermatology clinics' patient records.
Results Patients followed up in rheumatology (n: 40) were classified as Group 1, and patients followed up in ophthalmology (n: 49) and dermatology (n: 5) as Group 2. In Group 1, genital ulcers, erythema nodosum (p=0.009, p=0.003, respectively), lower extremity deep vein thrombosis, arterial aneurysm and neurological involvement were more common (p=0.005, p=0.008, p=0.001, respectively). In Group 2, the use of cyclosporine and interferon-α before the anti-TNF agent was higher (p<0.001, p<0.001, respectively), and the use of cyclophosphamide were higher in Group 1 (p<0.001). Both groups preferred infliximab, and ocular involvement was the most common reason for starting.
Conclusions While TNF-α inhibitors were chosen equally across departments, conventional medicines, including cyclosporine, cyclophosphamide, and interferon-α, were not. This choice was determined by the departments' experience and the clinical traits that predominated.
Behcet dermatology ophthalmology rheumatology TNF-α inhibitor
Yok
Birincil Dil | İngilizce |
---|---|
Konular | İç Hastalıkları |
Bölüm | Original Articles |
Yazarlar | |
Proje Numarası | Yok |
Yayımlanma Tarihi | 29 Ocak 2023 |
Gönderilme Tarihi | 18 Temmuz 2022 |
Kabul Tarihi | 18 Kasım 2022 |
Yayımlandığı Sayı | Yıl 2023 Cilt: 5 Sayı: 1 |